43.17
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Trend Tracker for (PRAX) - news.stocktradersdaily.com
Praxis Precision Medicines (NASDAQ:PRAX) Given Buy Rating at Needham & Company LLC - Defense World
Needham Reiterates Buy Rating on Praxis Precision Medicine (PRAX) with $80 Price Target | PRAX Stock News - GuruFocus
Bank of America Corp DE Reduces Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
California State Teachers Retirement System Acquires 275 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 2,747 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Ameriprise Financial Inc. Buys Shares of 3,227 Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Day 8 of Gains Streak for Praxis Precision Medicines Stock with 23% Return (vs. -42% YTD) [6/6/2025] - Trefis
Weston investment banker pleads guilty to insider trading offense - Westfair Communications
Trading (PRAX) With Integrated Risk Controls - news.stocktradersdaily.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Und - GuruFocus
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines Strengthens Talent Acquisition with New RSU Grant Program - Stock Titan
Can PRAX Rebound On Multiple Upcoming Epilepsy Trial Readouts? - RTTNews
Two Sigma Investments LP Lowers Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given a $97.00 Price Target at Oppenheimer - Defense World
Oppenheimer assigns outperform rating to Praxis Precision Medicines stock By Investing.com - Investing.com Canada
Oppenheimer Sets Price Target of $97 on PRAX with Outperform Rat - GuruFocus
Oppenheimer Sets Price Target of $97 on PRAX with Outperform Rating | PRAX Stock News - GuruFocus
Oppenheimer assigns outperform rating to Praxis Precision Medicines stock - Investing.com
Praxis Precision (PRAX) Gains Positive Outlook from Oppenheimer | PRAX Stock News - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 5.6% – Time to Sell? - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Reduced by BNP Paribas Financial Markets - Defense World
(PRAX) Trading Report - news.stocktradersdaily.com
Deutsche Bank AG Buys 5,009 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines to Participate in Upcoming Conferences - GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Conferences | PRAX Stock News - GuruFocus
What is Chardan Capital’s Forecast for PRAX FY2025 Earnings? - Defense World
Dimensional Fund Advisors LP Decreases Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Northern Trust Corp Raises Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
(PRAX) Investment Report - news.stocktradersdaily.com
Piper Sandler maintains Praxis stock at $270 target, bullish stance By Investing.com - Investing.com India
Praxis Precision Medicines (NASDAQ:PRAX) Research Coverage Started at Chardan Capital - Defense World
Praxis Precision Medicines (PRAX) to Release Earnings on Monday - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Analytical Lens: Exploring Praxis Precision Medicines Inc (PRAX)’s Financial Story Through Ratios - DWinneX
3,008 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Bought by Envestnet Asset Management Inc. - Defense World
Wedbush Has Positive Outlook for PRAX Q2 Earnings - Defense World
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - NewsBreak: Local News & Alerts
HC Wainwright Issues Negative Forecast for PRAX Earnings - Defense World
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Benzinga
Chardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation - Nasdaq
Chardan Capital Initiates Coverage on PRAX with a Buy Rating | PRAX Stock News - GuruFocus
Chardan Initiates Praxis Precision Medicines at Buy With $80 Price Target - marketscreener.com
Chardan Initiates Coverage on Praxis Precision (PRAX) with Buy Rating | PRAX Stock News - GuruFocus
Analysts Issue Forecasts for PRAX Q4 Earnings - Defense World
HC Wainwright Has Bearish Forecast for PRAX FY2029 Earnings - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given New $28.00 Price Target at Wedbush - Defense World
Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines (NASDAQ:PRAX) Receives “Buy” Rating from Needham & Company LLC - Defense World
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event - GlobeNewswire
Praxis Precision Medicines: Advancements and Financial Outlook - TipRanks
Wedbush Adjusts Price Target for Praxis Precision Medicine (PRAX - GuruFocus
Wedbush Adjusts Price Target for Praxis Precision Medicine (PRAX) | PRAX Stock News - GuruFocus
자본화:
|
볼륨(24시간):